ZTSZoetis Inc.

$54B

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.2B+6.2% YoY

Gross Profit

$1.5B70.5% margin

Operating Income

$834M38.3% margin

Net Income

$671M30.8% margin

EPS (Diluted)

$1.45

QoQ Revenue Growth

+9.0%

Cash Flow

Operating Cash Flow

$183M

Free Cash Flow

$17M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$13.7B

Total Liabilities

$9.1B

Stockholders' Equity

$4.6B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.2B	$2.1B	+6.2%
Gross Profit	$1.5B	$1.4B	+10.5%
Operating Income	$834M	$726M	+14.9%
Net Income	$671M	$529M	+26.8%

Revenue Segments

Dogs and Cats

$1.4B67%

Cattle

$329M15%

Swine

$133M6%

Poultry

$131M6%

Horses

$65M3%

Fish

$52M2%

Geographic Segments

United States Segment

$1.2B54%

International Segment

$995M46%

ZTS Q2 2023 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena